Blood Res.  2019 Jun;54(2):151-153. 10.5045/br.2019.54.2.151.

First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia

• Kim DJ
• Jeong S
• Kong SG
• Lee HS

• KMID: 2451018
• DOI: http://doi.org/10.5045/br.2019.54.2.151

Abstract

No abstract available.

MeSH Terms

Latent Tuberculosis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

Figure

• 

  Fig. 1 Computed tomography scan of the chest. Lung setting view image showed diffuse subtle ground glass opacities in the hemithoraces, and atypical pneumonia such as viral infection, pneumocystis pneumonia, miliary TB, or drug-induced pneumonitis was suspected.

• 

  Fig. 2 Changes in BCR-ABL real-time quantitative PCR (RQ-PCR) results according to antituberculosis medication and CML medication. After antituberculosis medication, BCR-ABL RQ-PCR results remained relatively stable and showed a major molecular response.

Reference

1. Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors. Biomark Insights. 2016; 10:Suppl 3. 55–68.

2. Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2009; 33:670–672.

3. Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol. 2009; 90:383–387.

4. Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003; 9:976–980.

5. García-Muñoz R, Galar A, Moreno C, et al. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma. 2007; 48:2461–2464.

6. Senn L, Kovacsovics T, Tarr PE, Meylan P. Peritoneal tuberculosis after imatinib therapy. Arch Intern Med. 2009; 169:312–313.

7. Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005; 105:2473–2479.

8. Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008; 12:2107–2118.

9. Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol. 2008; 36:1297–1308.

10. de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013; 122:227–238.

11. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362:2251–2259.